Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Lophius Biosciences Joins NEU² Program

Published: Wednesday, June 19, 2013
Last Updated: Wednesday, June 19, 2013
Bookmark and Share
Company receives substantial grant funding for the diagnosis and monitoring of multiple sclerosis.

Bionamics GmbH and Lophius Biosciences GmbH have announced that Lophius Biosciences has joined the NEU² program with a project addressing the development of T-Track® MS as a novel blood-based diagnostic test supporting the initial diagnosis of multiple sclerosis (MS) and enabling the monitoring of MS disease progression.

This new project is to last for about two years with a funding of > 350.000 EUR proportionally supplied by The Federal Ministry of Education and Research (BMBF) under the BioPharma initiative.

Lophius Biosciences is a leading developer of innovative T cell based diagnostic test systems. One of the company’s platform technologies, the “Reverse T Cell Technology (RTT)”, represents a novel strategy for the diagnosis of T cell-mediated diseases.

In contrast to available methods, RTT exploits the maturation processes induced in antigen presenting cells (APC) via a specific interaction with activated T helper (Th) cells thus representing an indirect measure for activated Th cells.

Due to the high specificity of RTT for activated Th cells, the intended use of the RTT assay is the reliable detection of disease-specific activated Th cells as a novel biomarker for the diagnosis and monitoring of ongoing autoimmune diseases such as MS.

The T-Track® MS test is aimed to fulfill unmet clinical needs offering a blood-based rapid and reliable differential diagnosis of MS complementary to the today’s clinical and MRT based diagnosis.

Initial data from a collaboration between Lophius Biosciences and the Clinic and Policlinic for Neurology, University of Regensburg, and the Institute for Neuroimmunology and Clinical MS Research, Center for Molecular Neurobiology Hamburg, demonstrated preliminary clinical proof of principle for this MS test.

Dr. Michael Lutz and Prof. Dr. Ralf Wagner, Managing Directors of Lophius Biosciences commented: “We are very pleased to join the NEU² consortium. Both the opportunity to interact with leading experts in the MS field as well as the substantial funding will accelerate the development of our highly innovative T cell based diagnostic T-Track® MS test kit and help Lophius to initiate a broader clinical discovery and development program.”

Dr. Timm Jessen, CEO of Bionamics GmbH and founder of NEU², about the further expansion of the NEU² consortium: “With Lophius Biosciences we could attract an attractive new partner for the consortium. Its expertise in the diagnostic area will complement our expertises within NEU², also to the benefit of our current consortium members.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Lophius Biosciences Appoints Dr. Robert Phelps as Director Business Operations
Dr. Phelps has longstanding experience in business development and licensing.
Wednesday, December 04, 2013
Lophius Biosciences Closes Financing Round and Expands Management Board
Lophius Biosciences announces the closing of a further financing round with Prof. Dr Ralf Wagner been appointed as Managing Director.
Tuesday, January 22, 2013
Lophius Biosciences Concludes TB Detection Trials
Company achieves first clinical Proof of Principle for T-Track® TB for detection of active tuberculosis and receives research funding.
Thursday, November 08, 2012
Lophius Biosciences Completes Necessary Regulatory Milestones with EN ISO 13485 Certification
Company has received CE-marking for its T-Track® CMV and T-Track® EBV tests.
Friday, June 01, 2012
Lophius Biosciences Closes Additional Financing Round with Current Investors Totaling 1.4 Million EUR
Financial investors such as S-Refit, High-Tech Gründerfonds and Bayernkapital participated in this financing round.
Tuesday, July 19, 2011
Lophius Biosciences Expands its Management Team and Prepares for Market Entry at the Beginning of 2012
The team is completed by Dr. Zanker from MedicalDevice+, an experienced expert in the field of regulatory affairs for diagnostic products.
Tuesday, July 12, 2011
Scientific News
Point of Care Diagnostics - A Cautious Revolution
Advances in molecular biology, coupled with the miniaturization and improved sensitivity of assays and devices in general, have enabled a new wave of point-of-care (POC) or “bedside” diagnostics.
ReadCoor Launched to Commercialize 3D Sequencing Tech
ReadCoor will leverage the Wyss Institute’s method for simultaneously sequencing and mapping RNAs within cells and tissues to advance development of diagnostics.
Crispr Toolbox Expanded By Protein
Researchers have shown a newly discovered CRISPR protein has two distinct RNA cutting activities.
Heart Arrhythmia Caused by Mosaic of Mutant Cells
Researchers have solved the genetic mystery of an infant suffering from heart arrhythmia.
Over Two-Thirds of Cervical Cancer Deaths Prevented
Cervical screening prevents 70% of cervical cancer deaths and if all eligible women regularly attended screening this would rise to 83%.
Detecting Bacterial Infections in Newborns
Researchers tested an alternative way to diagnose bacterial infections in infants—by analyzing RNA biosignatures from a small blood sample.
Case for Liquid Biopsies Builds in Advanced Lung Cancer
Study addresses unmet need for better, non-invasive tests called out in recent "Moonshot" blue ribbon panel report
Mechanisms of Parkinson’s Pathology
Defects that lead to cells’ failure to decommission faulty mitochondria cause nerve cells to die, triggering the symptoms of Parkinson’s disease.
Genetic Misdiagnoses of Heart Condition
Analysis found several genetic variations previously linked with a heart condition were harmless, leading to condition misdiagnosis.
Opening Door to Oesophageal Cancer Targeted Treatments
Scientists have discovered that oesophageal cancer can be classified into three different subtypes.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!